Stent thrombosis (ST) seldom happens, however, once this complication occurs, it may result in life-threatening catastrophic events such as trans-mural myocardial infarction or sudden cardiac death. We should clarify the mechanism of ST to prevent serious complications. In the Bern-Rotterdam registry, at three years, the cumulative incidence of angiographic ST was 2.9%, with early stent thrombosis occurring in 60% and late stent thrombosis in 40%. Late stent thrombosis occurred steadily at a constant rate of 0.6% per year up to three years after stent implantation [1] . From the SCAAR registry, the cumulative rates of ST at two years for first-generation drug-eluting stents (DES) (sirolimus-, paclitaxel-, and Endeavor ® zotarolimus-eluting stents, Medtronic, Minneapolis, MN, USA) was 1.3% and second-generation DES (everolimus-and Endeavor ® Resolute zotarolimus-eluting stents, Medtronic) was 0.6% (a 43% lower risk of definite ST compared with first-generation DES) [2] .
Definition of ST
The definition of ST was proposed by the Academic Research Consortium, as Definite: angiographic confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or electorcardiographic signs of acute ischemia or typical rise and fall of in cardiac biomarkers within 48 h of angiography or pathologic confirmation of ST determined at autopsy or from tissue obtained following thrombectomy [3] . The case reported by Ishikawa et al. [4] is considered as definite ST, because emergency coronary angiography showed a total occlusion at the overlapping site of the 2 paclitaxeleluting stents (PESs) with thrombus resulting in acute myocardial infarction.
Mechanism of ST
ST may occur acutely (within 24 h), subacutely (within 30 days), late (within one year), or very late (more than one year) after stent placement. The mechanism for ST involves multiple factors, such as procedural, patient, lesion, and stent characteristics as well as the cessation of dual antiplatelet therapy (DAPT) [5] . We consider that early ST is mainly related to procedural factors such as stent under expansion or stent edge dissection, and late to very late ST is related to stent fracture [6] , incomplete neointimal coverage (Fig. 1) , atypical vessel reaction [7] , neo-atherosclerosis in neointima [8] , and cessation of DAPT ( Table 1 ). The timing of ST of the reported case was 17 months after percutaneous coronary intervention. Thus it is categorized as very late ST. In this case, surprisingly, full neointimal coverage was observed, and there were no findings of stent malapposition and also DAPT had been continued. The only abnormal finding was the high range of normalized standard deviation values in optical coherence tomography (OCT) image of neointima suggesting abnormal immature neointima. According to my experience, OCT findings of homogeneous high intensity neointima show generally matured white neointima by angioscopy, and that of heterogeneous neointima was yellow neointima mixed with red thrombus (Fig. 2) . The authors speculated that allergic action in neointima had thrombogenicity and formed thrombus involving inflammatory cells. I estimate that lack of endothelial cells or endothelial dysfunction may play a part in thrombogenicity. However, we have no feasible method to visualize endothelial cells and to evaluate endothelial function in clinical practice. Further 
Clinical implication of this case report
Disappointingly, according to this case report, even though full neointimal coverage was observed by OCT, we may not say that the risk of ST had disappeared. Also, even though DAPT was continued, ST may happen. The optimal duration of DAPT remains ambiguous and we should always be cautious about ST. To whom we can say that you are safe from ST remains to be clarified.
